Home
COLL
COLL News

Latest Collegium Pharmaceutical Inc. (COLL) News on February 22, 2025

Argus Research

3 days ago

COLL: Lowering target price to $31.00

Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

GlobeNewswire

9 days ago

Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

Collegium Appoints Nancy S. Lurker to its Board of Directors

GlobeNewswire

17 days ago

Collegium Appoints Nancy S. Lurker to its Board of Directors

Argus Research

17 days ago

COLL: Lowering target price to $32.00

Argus Research

24 days ago

COLL: Lowering target price to $34.00

Argus Research

a month ago

COLL: What does Argus have to say about COLL?

MT Newswires

a month ago

Collegium Pharmaceutical Insider Sold Shares Worth $908,628, According to a Recent SEC Filing

MT Newswires

a month ago

Needham Upgrades Collegium Pharmaceutical to Buy From Hold, Price Target is $46

Collegium Pharmaceutical Unveils 2025 Financial Projections

TipRanks

a month ago

Collegium Pharmaceutical Unveils 2025 Financial Projections

MT Newswires

a month ago

Collegium Pharmaceutical Shares Rise After 2025 Guidance

Collegium Provides 2025 Financial Guidance and Business Update

GlobeNewswire

a month ago

Collegium Provides 2025 Financial Guidance and Business Update

Pulling back 6.0% this week, Collegium Pharmaceutical's NASDAQ:COLL) three-year decline in earnings may be coming into investors focus

Simply Wall St.

2 months ago

Pulling back 6.0% this week, Collegium Pharmaceutical's NASDAQ:COLL) three-year decline in earnings may be coming into investors focus

Argus Research

2 months ago

COLL: Lowering target price to $31.00

Argus Research

2 months ago

COLL: What does Argus have to say about COLL?

Argus Research

2 months ago

COLL: What does Argus have to say about COLL?

Argus Research

3 months ago

COLL: Lowering target price to $32.00

Argus Research

3 months ago

COLL: Raising target price to $33.00

Collegium Pharmaceutical's (NASDAQ:COLL) Performance Is Even Better Than Its Earnings Suggest

Simply Wall St.

3 months ago

Collegium Pharmaceutical's (NASDAQ:COLL) Performance Is Even Better Than Its Earnings Suggest

Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?

Zacks

3 months ago

Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?

Argus Research

3 months ago

COLL: Lowering target price to $33.00

Collegium to Participate in Upcoming Investor Conferences

GlobeNewswire

3 months ago

Collegium to Participate in Upcoming Investor Conferences

Collegium Pharmaceutical Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

3 months ago

Collegium Pharmaceutical Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

GuruFocus.com

3 months ago

Collegium Pharmaceutical Inc (COLL) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...

Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock?

Zacks

3 months ago

Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock?

Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings

Zacks

3 months ago

Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings

Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Lag Estimates

Zacks

3 months ago

Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Lag Estimates

Associated Press Finance

3 months ago

Collegium Pharmaceutical: Q3 Earnings Snapshot

Collegium Reports Record Third Quarter 2024 Financial Results

GlobeNewswire

3 months ago

Collegium Reports Record Third Quarter 2024 Financial Results

Collegium Appoints Vikram Karnani as Chief Executive Officer

GlobeNewswire

3 months ago

Collegium Appoints Vikram Karnani as Chief Executive Officer

What To Expect From Collegium Pharmaceutical Inc (COLL) Q3 2024 Earnings

GuruFocus.com

4 months ago

What To Expect From Collegium Pharmaceutical Inc (COLL) Q3 2024 Earnings

Argus Research

4 months ago

COLL: Lowering target price to $35.00

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks

4 months ago

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Collegium Pharmaceutical to Report Q3 Earnings: What's in the Cards?

Zacks

4 months ago

Collegium Pharmaceutical to Report Q3 Earnings: What's in the Cards?

Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?

Zacks

4 months ago

Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?

Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024

GlobeNewswire

4 months ago

Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024

Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?

Zacks

4 months ago

Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?

GuruFocus.com

4 months ago

Collegium Pharmaceutical Inc (COLL) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Argus Research

4 months ago

COLL: Lowering target price to $40.00

Breakouts Boost These Three Stocks To All-Time Highs

Investor's Business Daily

5 months ago

Breakouts Boost These Three Stocks To All-Time Highs

Should We Be Delighted With Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) ROE Of 46%?

Simply Wall St.

5 months ago

Should We Be Delighted With Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) ROE Of 46%?

Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?

Zacks

5 months ago

Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?

Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?

Zacks

5 months ago

Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?

Collegium Pharmaceutical (COLL) Upgraded to Buy: Here's Why

Zacks

5 months ago

Collegium Pharmaceutical (COLL) Upgraded to Buy: Here's Why

Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?

Zacks

5 months ago

Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?

Insider Sale: EVP and General Counsel Shirley Kuhlmann Sells 20,225 Shares of Collegium ...

GuruFocus.com

5 months ago

Insider Sale: EVP and General Counsel Shirley Kuhlmann Sells 20,225 Shares of Collegium ...

MT Newswires

5 months ago

Collegium Pharmaceutical Insider Sold Shares Worth $773,792, According to a Recent SEC Filing

MT Newswires

6 months ago

Collegium Closes Acquisition of Ironshore Therapeutics; Boosts 2024 Product Revenue

Collegium Completes Acquisition of Ironshore Therapeutics

GlobeNewswire

6 months ago

Collegium Completes Acquisition of Ironshore Therapeutics

Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire

6 months ago

Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Collegium Announces Eight Poster Presentations at PAINWeek Conference 2024

GlobeNewswire

6 months ago

Collegium Announces Eight Poster Presentations at PAINWeek Conference 2024

Argus Research

6 months ago

COLL: Raising target price to $40.00

Argus Research

6 months ago

COLL: Raising target price to $38.00

Shareholders Will Be Pleased With The Quality of Collegium Pharmaceutical's (NASDAQ:COLL) Earnings

Simply Wall St.

6 months ago

Shareholders Will Be Pleased With The Quality of Collegium Pharmaceutical's (NASDAQ:COLL) Earnings

Collegium Pharmaceutical (COLL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks

6 months ago

Collegium Pharmaceutical (COLL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates

Zacks

6 months ago

Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates

Associated Press Finance

6 months ago

Collegium Pharmaceutical: Q2 Earnings Snapshot

Collegium Reports Second Quarter 2024 Financial Results

GlobeNewswire

6 months ago

Collegium Reports Second Quarter 2024 Financial Results

Unveiling Collegium Pharmaceutical (COLL) Q2 Outlook: Wall Street Estimates for Key Metrics

Zacks

6 months ago

Unveiling Collegium Pharmaceutical (COLL) Q2 Outlook: Wall Street Estimates for Key Metrics

Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

7 months ago

Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?

Zacks

7 months ago

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?

Collegium Pharmaceutical (COLL) Soars 10.6%: Is Further Upside Left in the Stock?

Zacks

7 months ago

Collegium Pharmaceutical (COLL) Soars 10.6%: Is Further Upside Left in the Stock?

Collegium buys Ironshore for $525m and enter ADHD market

Pharmaceutical Technology

7 months ago

Collegium buys Ironshore for $525m and enter ADHD market

MT Newswires

7 months ago

Collegium Pharmaceutical to Acquire Ironshore Therapeutics for $525 Million

Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology

GlobeNewswire

7 months ago

Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology

Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024

GlobeNewswire

7 months ago

Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024

Argus Research

7 months ago

COLL: Raising target price to $35.00

Argus Research

7 months ago

COLL: Raising target price to $34.00

Argus Research

7 months ago

COLL: Lowering target price to $33.00

Collegium Pharmaceutical (NASDAQ:COLL) shareholders have earned a 19% CAGR over the last five years

Simply Wall St.

8 months ago

Collegium Pharmaceutical (NASDAQ:COLL) shareholders have earned a 19% CAGR over the last five years

MT Newswires

8 months ago

Collegium Pharmaceutical Says Nucynta Gets FDA Pediatric Exclusivity

Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise

GlobeNewswire

8 months ago

Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Upgraded by Jefferies

Insider Monkey

8 months ago

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Upgraded by Jefferies

Investing.com

8 months ago

Street calls of the week: Upgrades for Best Buy and Lululemon

Insider Sale: EVP and General Counsel Shirley Kuhlmann Sells 25,000 Shares of Collegium ...

GuruFocus.com

9 months ago

Insider Sale: EVP and General Counsel Shirley Kuhlmann Sells 25,000 Shares of Collegium ...

MT Newswires

9 months ago

Collegium Pharmaceutical Insider Sold Shares Worth $814,180, According to a Recent SEC Filing

Insider Sale: EVP & CFO Colleen Tupper Sells Shares of Collegium Pharmaceutical Inc (COLL)

GuruFocus.com

9 months ago

Insider Sale: EVP & CFO Colleen Tupper Sells Shares of Collegium Pharmaceutical Inc (COLL)

Collegium to Participate in Jefferies Global Healthcare Conference

GlobeNewswire

9 months ago

Collegium to Participate in Jefferies Global Healthcare Conference

MT Newswires

9 months ago

Collegium Pharmaceutical Launches $35 Million Accelerated Share Repurchase Program

Collegium Announces $35 Million Accelerated Share Repurchase Program

GlobeNewswire

9 months ago

Collegium Announces $35 Million Accelerated Share Repurchase Program

Collegium Pharmaceutical Reports First Quarter 2024 Earnings

GuruFocus.com

9 months ago

Collegium Pharmaceutical Reports First Quarter 2024 Earnings

Associated Press Finance

9 months ago

Sweetgreen, Natera rise; Collegium Pharmaceutical, Akamai fall, 5/10/2024

Associated Press

9 months ago

Sweetgreen, Natera rise; Collegium Pharmaceutical, Akamai fall, 5/10/2024

MT Newswires

9 months ago

--Needham Downgrades Collegium Pharmaceutical to Hold From Buy

Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Looks Like They Deserve Their Pay Packet

Simply Wall St.

9 months ago

Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Looks Like They Deserve Their Pay Packet

MT Newswires

9 months ago

Collegium Pharmaceutical Q1 Adjusted Net Income, Revenue Rise; 2024 Outlook Reiterated

Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

9 months ago

Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Lag Estimates

Zacks

9 months ago

Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Lag Estimates

Associated Press Finance

9 months ago

Collegium Pharmaceutical: Q1 Earnings Snapshot

Collegium Reports First Quarter 2024 Financial Results

GlobeNewswire

9 months ago

Collegium Reports First Quarter 2024 Financial Results

Collegium Announces CEO Transition

GlobeNewswire

9 months ago

Collegium Announces CEO Transition

Unlocking Q1 Potential of Collegium Pharmaceutical (COLL): Exploring Wall Street Estimates for Key Metrics

Zacks

9 months ago

Unlocking Q1 Potential of Collegium Pharmaceutical (COLL): Exploring Wall Street Estimates for Key Metrics

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks

10 months ago

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Collegium (COLL) to Report Q1 Earnings: Here's What to Expect

Zacks

10 months ago

Collegium (COLL) to Report Q1 Earnings: Here's What to Expect

Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER

GlobeNewswire

10 months ago

Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER

Collegium to Report First Quarter 2024 Financial Results on May 9, 2024

GlobeNewswire

10 months ago

Collegium to Report First Quarter 2024 Financial Results on May 9, 2024

Argus Research

10 months ago

COLL: Rating increased to a BUY

Is Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) ROE Of 25% Impressive?

Simply Wall St.

10 months ago

Is Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) ROE Of 25% Impressive?

Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026

GlobeNewswire

10 months ago

Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026

Collegium Pharmaceutical (COLL) Stock Sinks As Market Gains: What You Should Know

Zacks

10 months ago

Collegium Pharmaceutical (COLL) Stock Sinks As Market Gains: What You Should Know

Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire

a year ago

Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference

Share on Social Networks: